Mallinckrodt (MNK) Announces H.P. Acthar Gel Pilot Study Missed Primary Endpoint in SLE
Data presented yesterday by researchers for Mallinckrodt plc (NYSE: MNK) suggest that H.P. Acthar® Gel (repository corticotropin injection) reduces certain ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)